TelyRx Holdings (TSX:TELY) Research & Development: C$0.23 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:TELY TelyRx Holdings Inc TSX:TELY
12 GF Score
Price C$2.75
! 1 Warning Sign
View Full Analysis

What is TelyRx Holdings Research & Development?

TelyRx Holdings TSX:TELY +5.77% 12 Research & Development is C$0.23 Mil as of Mar. 2026. GuruFocus rates TSX:TELY with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TelyRx Holdings's Research & Development for the three months ended in Mar. 2026 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.23 Mil.

TelyRx Holdings  (TSX:TELY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TelyRx Holdings Research & Development Related Terms

TelyRx Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for TelyRx Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TelyRx Holdings Research & Development Chart

TelyRx Holdings Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
0.00 0.10 0.00

TelyRx Holdings Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial 0.07 0.00 0.23 0.00 0.00
TSX:TELY
12GF Score
TelyRx Holdings Inc TSX:TELY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TelyRx Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.23 Mil mean?
TelyRx Holdings (TSX:TELY) has a Research & Development of C$0.23 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on TelyRx Holdings and its competitors.
Is TelyRx Holdings' Research & Development too high?
TelyRx Holdings' current Research & Development is C$0.23 Mil. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' Research & Development compare to competitors?
TelyRx Holdings' Research & Development of C$0.23 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TelyRx Holdings and its competitors. TelyRx Holdings's current Research & Development is C$0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TSX:TELY) has a current Research & Development of C$0.23 Mil. The current Research & Development is C$0.23 Mil. TelyRx Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TelyRx Holdings (TSX:TELY), the current Research & Development is C$0.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TelyRx Holdings Business Description

Address 24761 US Highway 19 North, Clearwater, FL, USA, 33763
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score

Get the complete analysis for TSX:TELY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.75
Price